A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-01-26
AEs
4
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-23 (study day 13); relationship: N; serious criteria: hospitalization
mild
assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-22 (study day 254); relationship: N
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-28 (study day 321); relationship: not assessed
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-02-01 (study day 356); relationship: not assessed
Data queries
No data queries.